Ardelyx, Inc.
ARDX Real Time Price USDRecent trades of ARDX by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ARDX holdings by institutional investors
Quarterly net insider trading by ARDX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$500,000 Jul 16, 2026 Issue: Health Issues
-
$560,000 Apr 20, 2026 Issue: Health Issues
-
$580,000 Jan 19, 2026 Issue: Health Issues
-
$650,000 Oct 08, 2025 Issue: Health Issues
-
$620,000 Sep 16, 2025 Issue: Health Issues
-
$540,000 Jul 18, 2025 Issue: Health Issues Medicare/Medicaid
-
$670,000 Jan 17, 2025 Issue: Health Issues Medicare/Medicaid
-
$720,000 Oct 16, 2024 Issue: Health Issues
-
$530,000 Jul 10, 2024 Issue: Health Issues
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$80,000 Jan 21, 2024 Issue: Medicare/Medicaid
-
$60,000 Jan 20, 2024 Issue: Medicare/Medicaid Health Issues
-
$460,000 Oct 06, 2023 Issue: Medicare/Medicaid
-
$310,000 Jul 17, 2023 Issue: Medicare/Medicaid
-
$130,000 Jan 17, 2023 Issue: None
-
$50,000 Oct 20, 2022 Issue: Health Issues
-
$30,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid
-
$130,000 Jul 22, 2022 Issue: None
-
$130,000 Apr 20, 2022 Issue: None
-
$260,000 Jan 20, 2022 Issue: None
-
$240,000 Oct 20, 2021 Issue: None
-
$220,000 Jul 19, 2021 Issue: None
-
$190,000 Apr 19, 2021 Issue: None
-
$170,000 Jan 21, 2021 Issue: None
-
$30,000 Oct 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$30,000 Apr 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Oct 18, 2019 Issue: Medicare/Medicaid
-
$30,000 Jul 12, 2019 Issue: Medicare/Medicaid
-
$30,000 Apr 04, 2019 Issue: Medicare/Medicaid
-
$10,000 Jan 09, 2019 Issue: Medicare/Medicaid Health Issues
Former government officials who have lobbied for ARDX
17 former government officials from 15 congressional offices at 6 lobbying firms have lobbied for ARDX, most recently Jul 20, 2026.
-
John Ray House Legislative Assistant, Rep. Mike Kelly -
Keith Studdard House Legislative Director, Rep. Marsha Blackburn -
John Herzog Senate Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President -
Laura Kemper Senate Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services -
Brett Meeks Senate Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander
-
Kristin Fritsch House Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Senior Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Professional Staff Member House Committee on Energy and Commerce -
Beau Schuyler House Legislative Director: Rep. Tanner; Legislative Director: Rep. McIntyre -
Yul Edwards House Legislative Assistant/Chief of Staff, Rep. Danny K. Davis; Legislative Director, Rep. Frank Ballance, Jr.
ARDX Estimated quarterly lobbying spending
ARDX Revenue by Segment or Geography
New ARDX patent grants
-
Patent Title: Compounds useful for treating gastrointestinal tract disorders Apr. 22, 2025
-
Patent Title: Hormone receptor modulators for treating metabolic conditions and disorders Jan. 28, 2025
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Sep. 10, 2024
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Jun. 25, 2024
-
Patent Title: Glycyrrhetinic acid derivatives for use in treating hyperkalemia Jan. 02, 2024
-
Patent Title: Compounds and methods for inhibiting phosphate transport Nov. 14, 2023
-
Patent Title: Glycyrrhetinic acid derivatives for treating hyperkalemia Sep. 26, 2023
-
Patent Title: Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders Sep. 12, 2023
-
Patent Title: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators Aug. 08, 2023
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders May. 03, 2022
-
Patent Title: Compounds useful for treating gastrointestinal tract disorders Feb. 08, 2022
-
Patent Title: Inhibitors of nhe-mediated antiport Oct. 19, 2021
-
Patent Title: Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators Aug. 17, 2021
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Apr. 06, 2021
-
Patent Title: Nhe3-binding compounds and methods for inhibiting phosphate transport Mar. 09, 2021
-
Patent Title: Hormone receptor modulators for treating metabolic conditions and disorders Oct. 06, 2020
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Jan. 28, 2020
-
Patent Title: Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists Aug. 27, 2019
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug. 20, 2019
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug. 13, 2019
-
Patent Title: Nhe3-binding compounds and methods for inhibiting phosphate transport Apr. 30, 2019
-
Patent Title: Compositions and methods for treating hyperkalemia Mar. 20, 2018
-
Patent Title: Compositions and methods for treating hyperkalemia Jan. 16, 2018
-
Patent Title: Compositions and methods for treating hyperkalemia May. 23, 2017
-
Patent Title: Pharmaceutical compositions for treating hyperkalemia Jan. 24, 2017
-
Patent Title: Pharmaceutical compositions for treating hyperkalemia Jan. 17, 2017
-
Patent Title: Compositions and methods for treating hyperkalemia Sep. 06, 2016
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder Aug. 09, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Apr. 05, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 22, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 22, 2016
-
Patent Title: Compounds and methods for inhibiting phosphate transport Mar. 08, 2016
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Apr. 14, 2015
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Mar. 03, 2015
-
Patent Title: Compounds and methods for inhibiting phosphate transport Dec. 23, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 26, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 26, 2014
-
Patent Title: Compounds and methods for inhibiting phosphate transport Aug. 19, 2014
-
Patent Title: Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Sep. 24, 2013
Federal grants, loans, and purchases
- $1,991 2026-06-26 00:00:00 Agency: Department of Veterans Affairs
- $11,948 2026-06-26 00:00:00 Agency: Department of Veterans Affairs
- $3,999 2026-06-12 00:00:00 Agency: Department of Veterans Affairs
- $1,991 2026-04-09 00:00:00 Agency: Department of Veterans Affairs
- $11,948 2026-02-20 00:00:00 Agency: Department of Veterans Affairs
- $2,017 2025-12-31 00:00:00 Agency: Department of Veterans Affairs
- $2,017 2025-09-29 00:00:00 Agency: Department of Veterans Affairs
- $2,017 2025-09-19 00:00:00 Agency: Department of Veterans Affairs
- $12,100 2024-10-01 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-05-23 00:00:00 Agency: Department of Veterans Affairs
- $0 2024-04-29 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $6,049 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $0 2022-03-25 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded to ARDX from public contracts
Recent insights relating to ARDX
Recent picks made for ARDX stock on CNBC
ETFs with the largest estimated holdings in ARDX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ARDX stock a Buy, Sell, or Hold?
- What is the price target for $ARDX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ARDX stock?
- Who owns the most shares of $ARDX stock?
- What funds own $ARDX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ARDX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
- Address Fremont, CA
- Market Cap 934.6 million
- Employees 489
- Industrial Classification Pharmaceutical Preparations
Ardelyx, Inc. (ARDX) Historical Stock Prices
Ardelyx, Inc. (ARDX) closed at $3.62 on September 22, 2026. Over the past year its adjusted close ranged from $3.38 to $7.99. Daily prices go back to June 19, 2014, 3,082 trading days in all.
- 1 month-6.94%
- 3 months-41.42%
- Year to date-37.91%
- 1 year-41.80%
- 3 years-8.35%
- 5 years+168.15%
- Max-74.34%
Quiver Premium charts ARDX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | 3.54 | 3.63 | 3.47 | 3.62 | 3.62 | 3,988,939 |
| Sep 21, 2026 | 3.46 | 3.52 | 3.37 | 3.50 | 3.50 | 2,834,103 |
| Sep 18, 2026 | 3.38 | 3.44 | 3.33 | 3.42 | 3.42 | 6,443,091 |
| Sep 17, 2026 | 3.44 | 3.50 | 3.34 | 3.38 | 3.38 | 4,231,994 |
| Sep 16, 2026 | 3.40 | 3.43 | 3.34 | 3.39 | 3.39 | 5,377,948 |
| Sep 15, 2026 | 3.52 | 3.52 | 3.38 | 3.40 | 3.40 | 5,096,127 |
| Sep 14, 2026 | 3.60 | 3.60 | 3.51 | 3.52 | 3.52 | 4,364,487 |
| Sep 11, 2026 | 3.65 | 3.68 | 3.56 | 3.58 | 3.58 | 5,690,263 |
| Sep 10, 2026 | 3.77 | 3.78 | 3.61 | 3.62 | 3.62 | 4,047,355 |
| Sep 9, 2026 | 3.73 | 3.92 | 3.69 | 3.80 | 3.80 | 4,473,755 |
| Sep 8, 2026 | 3.76 | 3.80 | 3.71 | 3.77 | 3.77 | 2,958,736 |
| Sep 4, 2026 | 3.68 | 3.78 | 3.68 | 3.78 | 3.78 | 2,982,312 |
| Sep 3, 2026 | 3.80 | 3.83 | 3.69 | 3.71 | 3.71 | 3,470,482 |
| Sep 2, 2026 | 3.75 | 3.83 | 3.73 | 3.80 | 3.80 | 3,913,811 |
| Sep 1, 2026 | 3.78 | 3.81 | 3.75 | 3.76 | 3.76 | 3,647,210 |
| Aug 31, 2026 | 3.80 | 3.81 | 3.68 | 3.78 | 3.78 | 3,801,734 |
| Aug 28, 2026 | 3.81 | 3.90 | 3.75 | 3.81 | 3.81 | 5,133,520 |
| Aug 27, 2026 | 3.83 | 3.86 | 3.79 | 3.82 | 3.82 | 2,286,142 |
| Aug 26, 2026 | 3.85 | 3.89 | 3.77 | 3.83 | 3.83 | 2,916,874 |
| Aug 25, 2026 | 3.75 | 3.92 | 3.75 | 3.78 | 3.78 | 3,428,416 |
| Aug 24, 2026 | 3.88 | 3.89 | 3.73 | 3.74 | 3.74 | 5,216,758 |
| Aug 21, 2026 | 3.92 | 3.97 | 3.88 | 3.89 | 3.89 | 2,879,273 |
| Aug 20, 2026 | 4.04 | 4.07 | 3.86 | 3.90 | 3.90 | 4,565,257 |
| Aug 19, 2026 | 4.02 | 4.07 | 3.94 | 4.03 | 4.03 | 3,050,143 |
| Aug 18, 2026 | 4.05 | 4.09 | 3.89 | 3.92 | 3.92 | 4,041,483 |
| Aug 17, 2026 | 4.06 | 4.09 | 4.00 | 4.06 | 4.06 | 3,667,535 |
| Aug 14, 2026 | 3.93 | 4.07 | 3.86 | 4.06 | 4.06 | 3,978,332 |
| Aug 13, 2026 | 4.03 | 4.04 | 3.86 | 3.91 | 3.91 | 4,354,766 |
| Aug 12, 2026 | 3.94 | 4.01 | 3.89 | 3.97 | 3.97 | 4,954,857 |
| Aug 11, 2026 | 4.02 | 4.09 | 3.92 | 3.94 | 3.94 | 8,166,587 |
| Aug 10, 2026 | 4.05 | 4.12 | 3.90 | 4.00 | 4.00 | 10,814,226 |
| Aug 7, 2026 | 4.05 | 4.27 | 3.90 | 4.00 | 4.00 | 20,071,166 |
| Aug 6, 2026 | 4.89 | 5.00 | 4.82 | 4.87 | 4.87 | 7,283,060 |
| Aug 5, 2026 | 5.04 | 5.10 | 4.84 | 4.91 | 4.91 | 3,109,709 |
| Aug 4, 2026 | 5.02 | 5.03 | 4.82 | 5.01 | 5.01 | 3,130,089 |
| Aug 3, 2026 | 4.98 | 5.03 | 4.88 | 4.98 | 4.98 | 2,919,404 |
| Jul 31, 2026 | 5.04 | 5.05 | 4.92 | 4.95 | 4.95 | 2,762,690 |
| Jul 30, 2026 | 4.97 | 5.04 | 4.91 | 5.04 | 5.04 | 2,593,355 |
| Jul 29, 2026 | 5.08 | 5.10 | 4.97 | 5.00 | 5.00 | 2,183,328 |
| Jul 28, 2026 | 5.07 | 5.12 | 5.03 | 5.08 | 5.08 | 1,655,742 |
| Jul 27, 2026 | 5.13 | 5.21 | 5.06 | 5.06 | 5.06 | 1,811,016 |
| Jul 24, 2026 | 5.15 | 5.17 | 5.02 | 5.03 | 5.03 | 1,719,500 |
| Jul 23, 2026 | 5.00 | 5.15 | 4.97 | 5.13 | 5.13 | 2,074,421 |
| Jul 22, 2026 | 5.03 | 5.09 | 5.00 | 5.08 | 5.08 | 2,180,146 |
| Jul 21, 2026 | 5.09 | 5.12 | 4.98 | 5.09 | 5.09 | 3,795,123 |
| Jul 20, 2026 | 5.23 | 5.27 | 5.08 | 5.09 | 5.09 | 2,368,081 |
| Jul 17, 2026 | 5.01 | 5.24 | 5.00 | 5.20 | 5.20 | 3,274,381 |
| Jul 16, 2026 | 5.25 | 5.27 | 5.06 | 5.12 | 5.12 | 2,445,574 |
| Jul 15, 2026 | 5.11 | 5.32 | 5.02 | 5.30 | 5.30 | 2,669,683 |
| Jul 14, 2026 | 5.14 | 5.20 | 5.07 | 5.16 | 5.16 | 2,661,324 |
| Jul 13, 2026 | 5.25 | 5.28 | 5.04 | 5.14 | 5.14 | 2,929,499 |
| Jul 10, 2026 | 5.38 | 5.39 | 5.19 | 5.28 | 5.28 | 2,336,676 |
| Jul 9, 2026 | 5.43 | 5.45 | 5.33 | 5.38 | 5.38 | 2,171,532 |
| Jul 8, 2026 | 5.36 | 5.44 | 5.26 | 5.43 | 5.43 | 3,565,475 |
| Jul 7, 2026 | 5.36 | 5.56 | 5.29 | 5.38 | 5.38 | 4,576,020 |
| Jul 6, 2026 | 5.20 | 5.41 | 5.15 | 5.34 | 5.34 | 3,612,995 |
| Jul 2, 2026 | 5.18 | 5.28 | 5.14 | 5.27 | 5.27 | 3,208,570 |
| Jul 1, 2026 | 5.11 | 5.28 | 5.06 | 5.16 | 5.16 | 5,228,935 |
| Jun 30, 2026 | 5.19 | 5.25 | 4.93 | 5.10 | 5.10 | 7,361,391 |
| Jun 29, 2026 | 5.61 | 5.62 | 5.08 | 5.23 | 5.23 | 8,988,538 |
| Jun 26, 2026 | 6.06 | 6.27 | 5.45 | 5.55 | 5.55 | 17,524,272 |
| Jun 25, 2026 | 6.28 | 6.39 | 6.04 | 6.06 | 6.06 | 2,109,279 |
| Jun 24, 2026 | 6.28 | 6.38 | 6.14 | 6.19 | 6.19 | 2,892,716 |
| Jun 23, 2026 | 6.35 | 6.47 | 6.17 | 6.18 | 6.18 | 3,087,210 |
| Jun 22, 2026 | 6.09 | 6.42 | 6.08 | 6.37 | 6.37 | 4,905,851 |
| Jun 18, 2026 | 5.90 | 6.07 | 5.75 | 6.05 | 6.05 | 9,839,094 |
| Jun 17, 2026 | 5.70 | 5.95 | 5.70 | 5.84 | 5.84 | 3,424,545 |
| Jun 16, 2026 | 5.74 | 5.87 | 5.58 | 5.67 | 5.67 | 3,375,545 |
| Jun 15, 2026 | 5.79 | 5.84 | 5.62 | 5.68 | 5.68 | 3,105,302 |
| Jun 12, 2026 | 5.80 | 5.90 | 5.68 | 5.69 | 5.69 | 2,628,436 |
| Jun 11, 2026 | 5.64 | 5.90 | 5.54 | 5.79 | 5.79 | 3,651,913 |
| Jun 10, 2026 | 5.55 | 5.91 | 5.54 | 5.61 | 5.61 | 2,939,943 |
| Jun 9, 2026 | 5.65 | 5.72 | 5.48 | 5.60 | 5.60 | 2,977,989 |
| Jun 8, 2026 | 5.62 | 5.68 | 5.52 | 5.54 | 5.54 | 1,817,486 |
| Jun 5, 2026 | 5.43 | 5.64 | 5.39 | 5.56 | 5.56 | 4,589,691 |
| Jun 4, 2026 | 5.50 | 5.54 | 5.38 | 5.40 | 5.40 | 2,572,480 |
| Jun 3, 2026 | 5.53 | 5.60 | 5.31 | 5.42 | 5.42 | 3,821,295 |
| Jun 2, 2026 | 5.69 | 5.70 | 5.48 | 5.52 | 5.52 | 4,149,229 |
| Jun 1, 2026 | 6.00 | 6.00 | 5.73 | 5.73 | 5.73 | 2,628,558 |
| May 29, 2026 | 6.26 | 6.30 | 6.03 | 6.04 | 6.04 | 2,803,812 |
| May 28, 2026 | 6.13 | 6.34 | 6.11 | 6.25 | 6.25 | 1,980,587 |
| May 27, 2026 | 6.32 | 6.35 | 6.10 | 6.17 | 6.17 | 2,338,714 |
| May 26, 2026 | 6.16 | 6.29 | 6.08 | 6.25 | 6.25 | 2,605,399 |
| May 22, 2026 | 6.35 | 6.37 | 6.10 | 6.11 | 6.11 | 2,321,999 |
| May 21, 2026 | 6.18 | 6.44 | 6.09 | 6.35 | 6.35 | 2,927,620 |
| May 20, 2026 | 6.06 | 6.41 | 6.06 | 6.27 | 6.27 | 2,793,960 |
| May 19, 2026 | 6.12 | 6.24 | 6.03 | 6.09 | 6.09 | 2,357,869 |
| May 18, 2026 | 6.20 | 6.30 | 6.05 | 6.11 | 6.11 | 3,132,970 |
| May 15, 2026 | 6.38 | 6.41 | 6.21 | 6.23 | 6.23 | 3,244,106 |
| May 14, 2026 | 6.39 | 6.50 | 6.29 | 6.46 | 6.46 | 2,075,754 |
| May 13, 2026 | 6.44 | 6.50 | 6.17 | 6.38 | 6.38 | 7,236,325 |
| May 12, 2026 | 6.64 | 6.68 | 6.48 | 6.61 | 6.61 | 1,823,000 |
| May 11, 2026 | 6.80 | 6.83 | 6.57 | 6.61 | 6.61 | 4,044,595 |
| May 8, 2026 | 7.04 | 7.20 | 6.71 | 6.78 | 6.78 | 5,863,188 |
| May 7, 2026 | 7.08 | 7.19 | 6.93 | 6.98 | 6.98 | 3,921,689 |
| May 6, 2026 | 7.16 | 7.39 | 6.99 | 7.10 | 7.10 | 4,663,168 |
| May 5, 2026 | 7.30 | 7.42 | 6.94 | 7.13 | 7.13 | 5,857,545 |
| May 4, 2026 | 7.14 | 7.43 | 7.02 | 7.30 | 7.30 | 8,096,867 |
| May 1, 2026 | 6.00 | 7.06 | 6.00 | 6.88 | 6.88 | 11,630,914 |
| Apr 30, 2026 | 6.07 | 6.40 | 6.02 | 6.33 | 6.33 | 8,457,282 |
| Apr 29, 2026 | 5.94 | 6.10 | 5.82 | 6.01 | 6.01 | 3,414,482 |
| Apr 28, 2026 | 6.04 | 6.09 | 5.96 | 5.97 | 5.97 | 1,914,596 |
| Apr 27, 2026 | 5.93 | 6.16 | 5.93 | 5.99 | 5.99 | 2,679,407 |
| Apr 24, 2026 | 6.00 | 6.04 | 5.87 | 5.95 | 5.95 | 2,254,429 |
| Apr 23, 2026 | 6.03 | 6.17 | 5.88 | 5.96 | 5.96 | 2,031,873 |
| Apr 22, 2026 | 6.08 | 6.12 | 5.93 | 6.02 | 6.02 | 2,963,214 |
| Apr 21, 2026 | 6.33 | 6.37 | 5.88 | 5.96 | 5.96 | 3,963,908 |
| Apr 20, 2026 | 6.40 | 6.53 | 6.26 | 6.30 | 6.30 | 3,076,287 |
| Apr 17, 2026 | 6.44 | 6.54 | 6.28 | 6.45 | 6.45 | 3,361,507 |
| Apr 16, 2026 | 6.30 | 6.35 | 6.18 | 6.28 | 6.28 | 1,668,878 |
| Apr 15, 2026 | 6.37 | 6.46 | 6.21 | 6.30 | 6.30 | 3,432,292 |
| Apr 14, 2026 | 6.37 | 6.50 | 6.24 | 6.33 | 6.33 | 3,737,813 |
| Apr 13, 2026 | 6.18 | 6.41 | 6.17 | 6.33 | 6.33 | 2,963,942 |
| Apr 10, 2026 | 6.16 | 6.28 | 6.07 | 6.18 | 6.18 | 3,478,390 |
| Apr 9, 2026 | 6.05 | 6.17 | 5.95 | 6.13 | 6.13 | 2,582,294 |
| Apr 8, 2026 | 6.12 | 6.22 | 6.05 | 6.10 | 6.10 | 3,052,815 |
| Apr 7, 2026 | 5.92 | 5.96 | 5.73 | 5.95 | 5.95 | 1,803,695 |
| Apr 6, 2026 | 5.95 | 6.08 | 5.93 | 5.97 | 5.97 | 1,576,571 |
| Apr 2, 2026 | 5.88 | 6.04 | 5.82 | 5.94 | 5.94 | 2,400,586 |
| Apr 1, 2026 | 6.04 | 6.22 | 6.03 | 6.11 | 6.11 | 6,441,620 |
| Mar 31, 2026 | 5.69 | 6.04 | 5.68 | 5.99 | 5.99 | 5,472,707 |
| Mar 30, 2026 | 5.39 | 5.59 | 5.35 | 5.55 | 5.55 | 2,585,053 |
| Mar 27, 2026 | 5.62 | 5.71 | 5.44 | 5.48 | 5.48 | 2,520,500 |
| Mar 26, 2026 | 5.51 | 5.80 | 5.51 | 5.69 | 5.69 | 2,923,391 |
| Mar 25, 2026 | 5.45 | 5.73 | 5.45 | 5.64 | 5.64 | 2,509,879 |
| Mar 24, 2026 | 5.24 | 5.36 | 5.11 | 5.35 | 5.35 | 4,481,461 |
| Mar 23, 2026 | 5.44 | 5.50 | 5.28 | 5.31 | 5.31 | 3,926,854 |
| Mar 20, 2026 | 5.49 | 5.51 | 5.26 | 5.31 | 5.31 | 8,465,272 |
| Mar 19, 2026 | 5.50 | 5.54 | 5.30 | 5.50 | 5.50 | 3,407,873 |
| Mar 18, 2026 | 5.78 | 5.79 | 5.54 | 5.55 | 5.55 | 2,907,885 |
| Mar 17, 2026 | 5.82 | 5.89 | 5.79 | 5.83 | 5.83 | 2,185,930 |
| Mar 16, 2026 | 5.84 | 5.92 | 5.77 | 5.84 | 5.84 | 1,945,898 |
| Mar 13, 2026 | 5.70 | 5.89 | 5.65 | 5.78 | 5.78 | 2,775,139 |
| Mar 12, 2026 | 5.94 | 5.94 | 5.60 | 5.66 | 5.66 | 2,785,266 |
| Mar 11, 2026 | 6.07 | 6.12 | 5.91 | 5.99 | 5.99 | 2,248,496 |
| Mar 10, 2026 | 6.30 | 6.38 | 6.03 | 6.12 | 6.12 | 2,681,637 |
| Mar 9, 2026 | 6.14 | 6.27 | 6.02 | 6.17 | 6.17 | 3,286,842 |
| Mar 6, 2026 | 6.15 | 6.26 | 6.04 | 6.19 | 6.19 | 2,675,763 |
| Mar 5, 2026 | 6.62 | 6.72 | 6.25 | 6.27 | 6.27 | 3,564,071 |
| Mar 4, 2026 | 6.30 | 6.69 | 6.13 | 6.65 | 6.65 | 3,959,165 |
| Mar 3, 2026 | 6.34 | 6.34 | 6.08 | 6.22 | 6.22 | 2,721,520 |
| Mar 2, 2026 | 6.25 | 6.54 | 6.25 | 6.47 | 6.47 | 2,500,271 |
| Feb 27, 2026 | 6.55 | 6.63 | 6.34 | 6.55 | 6.55 | 3,603,900 |
| Feb 26, 2026 | 6.58 | 6.68 | 6.43 | 6.63 | 6.63 | 3,159,261 |
| Feb 25, 2026 | 6.49 | 6.78 | 6.37 | 6.56 | 6.56 | 4,739,538 |
| Feb 24, 2026 | 6.21 | 6.57 | 6.06 | 6.56 | 6.56 | 8,664,586 |
| Feb 23, 2026 | 5.66 | 5.88 | 5.55 | 5.75 | 5.75 | 7,057,814 |
| Feb 20, 2026 | 6.49 | 6.49 | 5.61 | 5.73 | 5.73 | 14,018,705 |
| Feb 19, 2026 | 6.80 | 6.86 | 6.60 | 6.74 | 6.74 | 6,947,791 |
| Feb 18, 2026 | 6.76 | 6.83 | 6.65 | 6.72 | 6.72 | 2,854,993 |
| Feb 17, 2026 | 7.01 | 7.01 | 6.72 | 6.76 | 6.76 | 3,566,232 |
| Feb 13, 2026 | 7.00 | 7.18 | 6.85 | 6.87 | 6.87 | 2,787,432 |
| Feb 12, 2026 | 7.25 | 7.33 | 6.96 | 7.01 | 7.01 | 2,346,807 |
| Feb 11, 2026 | 7.34 | 7.39 | 7.11 | 7.26 | 7.26 | 4,303,100 |
| Feb 10, 2026 | 7.34 | 7.43 | 7.22 | 7.30 | 7.30 | 2,242,211 |
| Feb 9, 2026 | 7.33 | 7.38 | 7.13 | 7.33 | 7.33 | 2,032,634 |
| Feb 6, 2026 | 7.15 | 7.34 | 6.99 | 7.32 | 7.32 | 3,183,737 |
| Feb 5, 2026 | 7.28 | 7.34 | 6.92 | 7.00 | 7.00 | 5,424,386 |
| Feb 4, 2026 | 7.75 | 7.77 | 7.35 | 7.38 | 7.38 | 2,822,340 |
| Feb 3, 2026 | 7.85 | 7.99 | 7.57 | 7.74 | 7.74 | 3,209,636 |
| Feb 2, 2026 | 7.72 | 8.02 | 7.67 | 7.79 | 7.79 | 2,655,975 |
| Jan 30, 2026 | 7.78 | 7.88 | 7.58 | 7.69 | 7.69 | 2,696,785 |
| Jan 29, 2026 | 7.89 | 7.99 | 7.73 | 7.85 | 7.85 | 2,361,683 |
| Jan 28, 2026 | 7.84 | 8.06 | 7.70 | 7.86 | 7.86 | 3,071,797 |
| Jan 27, 2026 | 8.00 | 8.11 | 7.79 | 7.89 | 7.89 | 2,852,563 |
| Jan 26, 2026 | 7.74 | 7.93 | 7.55 | 7.80 | 7.80 | 2,196,974 |
| Jan 23, 2026 | 7.92 | 8.40 | 7.76 | 7.77 | 7.77 | 4,237,791 |
| Jan 22, 2026 | 8.01 | 8.22 | 7.85 | 7.93 | 7.93 | 4,795,067 |
| Jan 21, 2026 | 7.79 | 8.17 | 7.75 | 7.99 | 7.99 | 8,193,223 |
| Jan 20, 2026 | 6.85 | 7.80 | 6.84 | 7.76 | 7.76 | 15,800,470 |
| Jan 16, 2026 | 7.06 | 7.15 | 6.73 | 6.75 | 6.75 | 4,339,719 |
| Jan 15, 2026 | 6.92 | 7.25 | 6.76 | 7.04 | 7.04 | 4,614,900 |
| Jan 14, 2026 | 7.02 | 7.09 | 6.82 | 6.89 | 6.89 | 3,275,002 |
| Jan 13, 2026 | 7.29 | 7.34 | 6.93 | 7.04 | 7.04 | 5,052,089 |
| Jan 12, 2026 | 7.63 | 7.74 | 7.17 | 7.36 | 7.36 | 7,173,410 |
| Jan 9, 2026 | 7.29 | 8.05 | 7.22 | 7.74 | 7.74 | 17,909,452 |
| Jan 8, 2026 | 6.17 | 7.10 | 6.12 | 7.00 | 7.00 | 15,594,502 |
| Jan 7, 2026 | 5.61 | 6.07 | 5.59 | 5.83 | 5.83 | 7,226,444 |
| Jan 6, 2026 | 6.03 | 6.12 | 5.53 | 5.56 | 5.56 | 5,055,836 |
| Jan 5, 2026 | 6.16 | 6.24 | 5.65 | 6.09 | 6.09 | 7,989,193 |
| Jan 2, 2026 | 5.84 | 6.40 | 5.81 | 6.15 | 6.15 | 8,296,431 |
| Dec 31, 2025 | 5.80 | 5.91 | 5.76 | 5.83 | 5.83 | 3,433,922 |
| Dec 30, 2025 | 5.82 | 5.99 | 5.72 | 5.80 | 5.80 | 2,948,125 |
| Dec 29, 2025 | 5.75 | 5.79 | 5.69 | 5.78 | 5.78 | 2,042,266 |
| Dec 26, 2025 | 5.93 | 5.95 | 5.73 | 5.74 | 5.74 | 2,047,865 |
| Dec 24, 2025 | 5.80 | 6.04 | 5.77 | 5.99 | 5.99 | 1,511,939 |
| Dec 23, 2025 | 5.83 | 5.84 | 5.72 | 5.80 | 5.80 | 1,977,970 |
| Dec 22, 2025 | 5.78 | 5.90 | 5.71 | 5.84 | 5.84 | 2,449,010 |
| Dec 19, 2025 | 5.68 | 5.85 | 5.63 | 5.68 | 5.68 | 6,549,071 |
| Dec 18, 2025 | 5.79 | 5.89 | 5.66 | 5.68 | 5.68 | 2,317,254 |
| Dec 17, 2025 | 5.97 | 6.06 | 5.78 | 5.79 | 5.79 | 2,861,015 |
| Dec 16, 2025 | 6.19 | 6.23 | 5.98 | 6.00 | 6.00 | 2,651,999 |
| Dec 15, 2025 | 6.21 | 6.41 | 6.14 | 6.20 | 6.20 | 2,676,285 |
| Dec 12, 2025 | 6.03 | 6.30 | 5.92 | 6.21 | 6.21 | 3,765,996 |
| Dec 11, 2025 | 5.91 | 6.04 | 5.83 | 5.90 | 5.90 | 2,415,065 |
| Dec 10, 2025 | 5.84 | 5.97 | 5.76 | 5.92 | 5.92 | 3,015,507 |
| Dec 9, 2025 | 5.86 | 6.00 | 5.80 | 5.80 | 5.80 | 2,405,724 |
| Dec 8, 2025 | 6.04 | 6.07 | 5.73 | 5.88 | 5.88 | 2,709,015 |
| Dec 5, 2025 | 5.87 | 6.20 | 5.77 | 5.98 | 5.98 | 4,062,151 |
| Dec 4, 2025 | 5.81 | 5.93 | 5.73 | 5.92 | 5.92 | 2,515,614 |
| Dec 3, 2025 | 5.56 | 5.83 | 5.56 | 5.77 | 5.77 | 2,580,586 |
| Dec 2, 2025 | 5.63 | 5.71 | 5.49 | 5.54 | 5.54 | 1,986,490 |
| Dec 1, 2025 | 5.84 | 5.85 | 5.58 | 5.59 | 5.59 | 2,606,406 |
| Nov 28, 2025 | 5.95 | 6.00 | 5.76 | 5.80 | 5.80 | 1,062,640 |
| Nov 26, 2025 | 5.83 | 6.02 | 5.66 | 5.93 | 5.93 | 2,818,285 |
| Nov 25, 2025 | 5.57 | 5.89 | 5.53 | 5.72 | 5.72 | 2,862,240 |
| Nov 24, 2025 | 5.41 | 5.50 | 5.38 | 5.50 | 5.50 | 2,357,498 |
| Nov 21, 2025 | 5.52 | 5.59 | 5.30 | 5.42 | 5.42 | 3,609,307 |
| Nov 20, 2025 | 5.63 | 5.80 | 5.50 | 5.55 | 5.55 | 2,903,261 |
| Nov 19, 2025 | 5.81 | 5.84 | 5.40 | 5.57 | 5.57 | 3,291,630 |
| Nov 18, 2025 | 5.87 | 5.89 | 5.70 | 5.81 | 5.81 | 2,511,655 |
| Nov 17, 2025 | 5.81 | 5.99 | 5.74 | 5.91 | 5.91 | 2,682,593 |
| Nov 14, 2025 | 5.74 | 5.95 | 5.71 | 5.86 | 5.86 | 2,887,296 |
| Nov 13, 2025 | 6.02 | 6.08 | 5.81 | 5.83 | 5.83 | 1,902,593 |
| Nov 12, 2025 | 6.13 | 6.25 | 5.96 | 6.04 | 6.04 | 3,190,102 |
| Nov 11, 2025 | 5.65 | 6.17 | 5.56 | 6.13 | 6.13 | 4,092,983 |
| Nov 10, 2025 | 5.70 | 5.78 | 5.63 | 5.65 | 5.65 | 2,259,642 |
| Nov 7, 2025 | 5.64 | 5.65 | 5.42 | 5.59 | 5.59 | 2,700,679 |
| Nov 6, 2025 | 5.95 | 5.99 | 5.64 | 5.65 | 5.65 | 2,818,113 |
| Nov 5, 2025 | 5.61 | 5.99 | 5.59 | 5.95 | 5.95 | 4,529,189 |
| Nov 4, 2025 | 5.83 | 6.04 | 5.59 | 5.60 | 5.60 | 4,534,580 |
| Nov 3, 2025 | 6.07 | 6.39 | 5.75 | 5.92 | 5.92 | 7,649,919 |
| Oct 31, 2025 | 6.43 | 6.73 | 5.86 | 6.06 | 6.06 | 18,733,329 |
| Oct 30, 2025 | 4.95 | 5.11 | 4.92 | 5.01 | 5.01 | 6,068,810 |
| Oct 29, 2025 | 5.10 | 5.11 | 4.91 | 4.96 | 4.96 | 4,585,470 |
| Oct 28, 2025 | 5.10 | 5.14 | 5.04 | 5.11 | 5.11 | 2,789,215 |
| Oct 27, 2025 | 5.09 | 5.18 | 5.06 | 5.10 | 5.10 | 2,231,385 |
| Oct 24, 2025 | 5.12 | 5.13 | 5.01 | 5.04 | 5.04 | 2,289,096 |
| Oct 23, 2025 | 5.17 | 5.21 | 5.05 | 5.06 | 5.06 | 2,799,182 |
| Oct 22, 2025 | 5.30 | 5.32 | 5.14 | 5.15 | 5.15 | 2,883,131 |
| Oct 21, 2025 | 5.09 | 5.34 | 5.07 | 5.29 | 5.29 | 3,484,853 |
| Oct 20, 2025 | 5.08 | 5.18 | 4.92 | 5.10 | 5.10 | 3,791,997 |
| Oct 17, 2025 | 5.02 | 5.06 | 4.91 | 5.03 | 5.03 | 2,635,744 |
| Oct 16, 2025 | 5.16 | 5.27 | 5.01 | 5.05 | 5.05 | 2,738,584 |
| Oct 15, 2025 | 5.04 | 5.16 | 5.00 | 5.13 | 5.13 | 3,015,052 |
| Oct 14, 2025 | 5.00 | 5.07 | 4.84 | 5.01 | 5.01 | 3,445,221 |
| Oct 13, 2025 | 4.94 | 5.08 | 4.71 | 5.01 | 5.01 | 4,786,738 |
| Oct 10, 2025 | 5.05 | 5.05 | 4.86 | 4.94 | 4.94 | 3,788,763 |
| Oct 9, 2025 | 5.05 | 5.16 | 5.00 | 5.06 | 5.06 | 2,923,591 |
| Oct 8, 2025 | 5.19 | 5.21 | 5.02 | 5.06 | 5.06 | 3,940,793 |
| Oct 7, 2025 | 5.20 | 5.23 | 5.08 | 5.17 | 5.17 | 4,707,816 |
| Oct 6, 2025 | 5.25 | 5.33 | 5.16 | 5.20 | 5.20 | 3,278,397 |
| Oct 3, 2025 | 5.25 | 5.35 | 5.24 | 5.26 | 5.26 | 3,252,833 |
| Oct 2, 2025 | 5.32 | 5.36 | 5.24 | 5.25 | 5.25 | 2,310,799 |
| Oct 1, 2025 | 5.48 | 5.53 | 5.33 | 5.36 | 5.36 | 2,973,502 |
| Sep 30, 2025 | 5.63 | 5.63 | 5.49 | 5.51 | 5.51 | 3,098,242 |
| Sep 29, 2025 | 5.57 | 5.68 | 5.50 | 5.63 | 5.63 | 3,692,715 |
| Sep 26, 2025 | 6.00 | 6.04 | 5.49 | 5.54 | 5.54 | 5,434,764 |
| Sep 25, 2025 | 6.13 | 6.14 | 5.92 | 5.96 | 5.96 | 3,377,585 |
| Sep 24, 2025 | 6.17 | 6.21 | 6.10 | 6.15 | 6.15 | 1,812,838 |
| Sep 23, 2025 | 6.19 | 6.22 | 6.09 | 6.15 | 6.15 | 1,707,550 |
| Sep 22, 2025 | 6.21 | 6.28 | 6.20 | 6.22 | 6.22 | 2,040,727 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at ARDX, per a recent SEC DEF 14A filing. We estimate that the median employee at ARDELYX, INC. is paid $239,432.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|